2026-07059NoticeWallet

FDA Greenlights Generics for Worm-Killing Biltricide Tablets

Published Date: 4/13/2026

Notice

Summary

The FDA has decided that BILTRICIDE (praziquantel) 600 mg tablets weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, helping patients access affordable treatment without delays. No changes in safety rules or extra costs are expected, so everyone can breathe easy and keep treating their conditions smoothly.

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

Generics Can Continue Seeking Approval

The FDA decided that BILTRICIDE (praziquantel) 600 mg tablets were not withdrawn from sale for safety or effectiveness. Because of that decision (published April 13, 2026), FDA will not begin procedures to withdraw approval of ANDAs that refer to this drug, and ANDAs referencing this product may be approved if they meet legal and regulatory requirements.

Potential Labeling Update for ANDA Applicants

The FDA said that if it determines the drug's labeling should be revised to meet current standards, it will tell ANDA applicants to submit updated labeling. This means companies seeking approval may need to prepare and submit revised labels if FDA advises them to do so.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
4/13/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register